company background image
4111 logo

Chi Sheng Pharma & Biotech TPEX:4111 Stock Report

Last Price

NT$27.55

Market Cap

NT$1.6b

7D

-1.4%

1Y

3.2%

Updated

24 Dec, 2024

Data

Company Financials

Chi Sheng Pharma & Biotech Co., Ltd

TPEX:4111 Stock Report

Market Cap: NT$1.6b

4111 Stock Overview

Engages in the manufacturing, processing, sale, and import and export trade of pharmaceuticals, medical products, cosmetics, health foods, and medical equipment in Taiwan and internationally. More details

4111 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends4/6

My Notes

Capture your thoughts, links and company narrative

Chi Sheng Pharma & Biotech Co., Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for Chi Sheng Pharma & Biotech
Historical stock prices
Current Share PriceNT$27.55
52 Week HighNT$34.90
52 Week LowNT$24.55
Beta0.22
1 Month Change2.80%
3 Month Change4.95%
1 Year Change3.18%
3 Year Change19.52%
5 Year Change10.87%
Change since IPO106.23%

Recent News & Updates

Recent updates

Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

Apr 06
Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Mar 10
A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 01
Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Jan 05
Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Dec 10
Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Shareholder Returns

4111TW PharmaceuticalsTW Market
7D-1.4%4.4%0.4%
1Y3.2%-0.2%28.7%

Return vs Industry: 4111 exceeded the TW Pharmaceuticals industry which returned -0.2% over the past year.

Return vs Market: 4111 underperformed the TW Market which returned 28.7% over the past year.

Price Volatility

Is 4111's price volatile compared to industry and market?
4111 volatility
4111 Average Weekly Movement1.9%
Pharmaceuticals Industry Average Movement3.6%
Market Average Movement4.4%
10% most volatile stocks in TW Market7.8%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 4111 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 4111's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1962n/an/awww.cscp.com.tw

Chi Sheng Pharma & Biotech Co., Ltd engages in the manufacturing, processing, sale, and import and export trade of pharmaceuticals, medical products, cosmetics, health foods, and medical equipment in Taiwan and internationally. Its products portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic agents; hormones and adrenal cortical steroids; autonomic nerves agents; antihistamines and antipruritics; antipyretics and analgesics; antitussives and anti-asthmas; gastro-intestinal preparations; local anesthetic preparations; hemodialysis concentrate and external solutions; peritoneal dialysis solutions; and others. The company also offers medical devices, fat emulsion products, anesthetic products, hemostatics solutions, food products, functional drinks, skin care products, and veterinary medicinal products.

Chi Sheng Pharma & Biotech Co., Ltd Fundamentals Summary

How do Chi Sheng Pharma & Biotech's earnings and revenue compare to its market cap?
4111 fundamental statistics
Market capNT$1.58b
Earnings (TTM)NT$71.47m
Revenue (TTM)NT$1.10b

22.0x

P/E Ratio

1.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4111 income statement (TTM)
RevenueNT$1.10b
Cost of RevenueNT$744.76m
Gross ProfitNT$359.16m
Other ExpensesNT$287.69m
EarningsNT$71.47m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.25
Gross Margin32.53%
Net Profit Margin6.47%
Debt/Equity Ratio3.3%

How did 4111 perform over the long term?

See historical performance and comparison

Dividends

3.6%

Current Dividend Yield

80%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:10
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chi Sheng Pharma & Biotech Co., Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Li-chun ChangJih Sun Securities Investment Consulting Co., Ltd.
Xiaowei HuangMasterlink Securities Corp.